Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Chronic Myeloid Leukemia (CML)
NCT00531310Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Jan 2003
- Primary completion
- Dec 2007
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of busulfan and fludarabine in chronic myeloid leukemia (CML) (2 arms), sponsored by Columbia University. Primary endpoint: Toxicity associated with reduced intensity therapy and allogeneic SCT. Started Jan 2003; status: terminated.
02
Drugs
busulfanfludarabine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00531310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531310.